Can Ozempic End Addiction? | Dhruv Khullar | TED

This video explores the surprising potential of GLP-1 drugs, originally developed for diabetes and obesity, to treat addiction by acting on the brain rather than just the body. Through Mary’s story, it shows how these medications quiet “alcohol noise” and reduce compulsive urges, with scientists now investigating them against alcohol, opioid, gambling, and other addictions as possible “moderation molecules” that calm dopamine spikes without extinguishing desire. The segment frames this breakthrough as a winding, unpredictable discovery—from Gila monster venom to addiction medicine—underscoring the value of basic scientific curiosity. It also argues that GLP-1s challenge ancient views of moderation, suggesting it is not merely a moral achievement but a physiological state, while emphasizing that these drugs complement—not replace—the cultural and political work needed to address addiction’s deeper roots like loneliness, trauma, and poverty. Ultimately, the video highlights that by freeing people from addictive urges, GLP-1s allow them to ask the fundamental question: “What type of life do I want?”—a chance every person deserves.

• ▶ 0:44 Mary’s friend revealed that starting Ozempic drastically reduced her drinking, which prompted Mary to join a GLP-1 clinical trial for alcohol addiction.
• ▶ 1:28 For Mary, the medication cleared “alcohol noise,” reducing compulsive urges and creating mental space for major life changes — showing GLP-1s affect the mind, not just the body.
• ▶ 2:44 The GLP-1 drug revolution was catalyzed when a scientist discovered that Gila monster venom contained a similar peptide that lasted for hours, unlike natural GLP-1.

• ▶ 3:03 GLP-1 drugs affect far more than digestion; their most surprising effects may occur in the brain, not the gut.

• ▶ 3:18 GLP-1s are being investigated as a tool against multiple addictions—alcohol, cocaine, gambling, smoking, and opioid cravings—and may target a “universal pathology” underlying addiction.

• ▶ 4:13 Proposed mechanisms include calming the brain’s reward system by limiting dopamine spikes (“calming the water without draining the pool”), easing withdrawal, and acting as “moderation molecules” rather than extinguishing desires.

• ▶ 6:10 The section opens with stark addiction treatment gaps: tens of thousands of opioid overdose deaths yearly, alcohol-related deaths have more than doubled since 2000, and no new FDA-approved medication for alcohol use disorder in 20 years.
• ▶ 6:37 GLP-1s followed a winding path from a Gila monster peptide to a diabetes medication, to an obesity drug, and now to a potential addiction treatment.
• ▶ 7:05 The broader lesson is that medical progress is unpredictable, so basic scientific curiosity matters—we can't know where the next big innovation will come from.

• ▶ 7:29 GLP-1s force a reconsideration of ancient wisdom, where moderation was seen as a moral achievement—epitomized by Aristotle’s view that virtue lies between extremes (e.g., courage between cowardice and recklessness).

• ▶ 8:26 The modern problem has shifted from scarcity and boredom to excess and distraction, since Aristotle never faced Doritos, TikTok, or opioids—technologies that exploit human vulnerabilities.

• ▶ 8:51 GLP-1s suggest moderation is not just a virtue but a physiological state, offering a new tool that complements—rather than replaces—the cultural and political work needed to address addiction’s root causes like loneliness, trauma, and poverty.

• ▶ 9:43 Addiction can take almost everything: a young woman's opioid-to-heroin addiction led to a fatal heart infection, and a father with liver failure left his six- and eight-year-old children asking when he could come home—"some of the hardest conversations" the speaker has had.
• ▶ 10:29 Mary explained that GLP-1s let her act on her deeper desire to reinvent herself—changing her habits, relationships, and self-image—so she could live alongside her desires instead of being ruled by them.
• ▶ 10:57 The central question Mary's freedom made possible—"what type of life do I want?"—is one every person deserves a chance to ask.

• ▶ 0:04 Mary’s Story and the Discovery of GLP-1 (0:04 - 3:03) - - Mary’s early drinking sets the stage for the discovery and development of GLP-1.
• ▶ 3:03 GLP-1, the Gut, and the Addicted Brain (3:03 - 6:10) - - GLP-1s shift from digestion to brain reward pathways, moderating cravings but with limits.
• ▶ 6:10 Treatment Gaps and the Winding Path of GLP-1s (6:10 - 7:29) - - Addiction treatment gaps meet GLP-1s’ surprising journey from Gila monster peptide to diabetes and obesity drug.
• ▶ 7:29 Aristotle, Excess, and the Biology of Moderation (7:29 - 9:33) - - GLP-1s reframe Aristotle’s moderation as a biological state, not just a virtue.
• ▶ 9:33 Addiction’s Toll and the Desired Life (9:33 - 11:06) - - Patient suffering and Mary’s freedom from ruling desires raise the question of a truly desired life.